Title: Professor of Surgery
Research: Liver physiology, pathology and molecular signatures. Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in North America and can lead to Type II diabetes, liver cirrhosis (requiring liver transplantation), liver cancer (hepatocellular cancer, ) and increase the probability of other types of cancer spreading to the liver (liver metastasis). With the help of our human tissue bank and technologies such as proteomics and genomics, we hope to find new therapies for these diseases
Expertise: Liver metastasis; liver ischemia/reperfusion injury; non-alcoholic liver disease; hepatocellullar carcinoma; neuroendocrine tumors; proteomics; tissue banking
peter.metrakos [at] muhc.mcgill.ca (Email)
Tel: 514-934-1934, ext. 31600
Summary of Work:
- The role of endothalial cell activation in a dog to porcine in vivo model of liver transplantation
- The role of endothelial cell activation in a dog to porcine in vitromodel of islet transplantation
2. Cancer Metastasis:
- The role of adhesion molecules in the establisyhment of colon cancer liver metastasis. Specifically the expression of E selectin in liver sinusoidol endothelial cells during the development of liver metastasis.
- The expression of proprotein convertases in colon cancer liver metastasis and the effect of their inhibition on cancer progression.
3. Hepatocellular Carcinoma:
- Clinical trial: The effect of intrahepatic arterial chemoembolization pre-liver transplantation on the outcome of patients with larger hepatocellular carcinoma.
- The effect of octreotide on hepatocellular cell line growth.